Sign in
4

Changes in Ownership

MoonLake Immunotherapeutics Filed Acc 0001213900-26-042629

Chief Financial Officer sold 87,795 shares at an average $18.95 ($1,663,935)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Bodenstedt Matthias · Chief Financial Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2026-04-09 Sale : show line 1 in the form 10b5-1 −85,870 $18.94 $1,626,378 1,190,435 D
2026-04-10 Sale : show line 2 in the form 10b5-1 −1,925 $19.51 $37,557 1,188,510 D
Open-market sales · 87,795 sh · avg $18.95 · $1,663,935
Loading xslF345X06/ownership.xml…